和黄医药(00013.HK)他泽司他新药上市申请已获国家药监局受理并予以优先审评

阿斯达克财经07-04

和黄医药(00013.HK) 公布，他泽司他(tazemetostat)用于治疗复发或难治性滤泡性淋巴瘤成人患者的新药上市申请已获国家药监局受理并予以优先审评。他泽司他是由益普生(Ipsen)旗下公司Epizyme开发的全球同类首创的EZH2甲基转移酶抑制剂，已获美国食品药监局(FDA)加速批准用于治疗特定的复发/难治性滤泡性淋巴瘤患者以及特定的晚期上皮样肉瘤患者。日本厚生劳动省亦已批准其用于治疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2448457394?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg","is_english":false,"pubTime":"2024-07-04 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2448457394","market":"sh","top_or_hot":-1,"title":"和黄医药(00013.HK)他泽司他新药上市申请已获国家药监局受理并予以优先审评","media":"阿斯达克财经","content":"<div>\n<p>和黄医药(00013.HK) 公布，他泽司他(tazemetostat)用于治疗复发或难治性滤泡性淋巴瘤成人患者的新药上市申请已获国家药监局受理并予以优先审评。他泽司他是由益普生(Ipsen)旗下公司Epizyme开发的全球同类首创的EZH2甲基转移酶抑制剂，已获美国食品药监局(FDA)加速批准用于治疗特定的复发/难治性滤泡性淋巴瘤患者以及特定的晚期上皮样肉瘤患者。日本厚生劳动省亦已批准其用于治疗...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361228/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药(00013.HK)他泽司他新药上市申请已获国家药监局受理并予以优先审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药(00013.HK)他泽司他新药上市申请已获国家药监局受理并予以优先审评\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-04 08:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361228/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>和黄医药(00013.HK) 公布，他泽司他(tazemetostat)用于治疗复发或难治性滤泡性淋巴瘤成人患者的新药上市申请已获国家药监局受理并予以优先审评。他泽司他是由益普生(Ipsen)旗下公司Epizyme开发的全球同类首创的EZH2甲基转移酶抑制剂，已获美国食品药监局(FDA)加速批准用于治疗特定的复发/难治性滤泡性淋巴瘤患者以及特定的晚期上皮样肉瘤患者。日本厚生劳动省亦已批准其用于治疗...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361228/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361228/latest-news/AAFN","article_id":"2448457394","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448457394","pubTimestamp":1720052340,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"和黄医药公布，他泽司他用于治疗复发或难治性滤泡性淋巴瘤成人患者的新药上市申请已获国家药监局受理并予以优先审评。他泽司他是由益普生旗下公司Epizyme开发的全球同类首创的EZH2甲基转移酶抑制剂，已获美国食品药监局加速批准用于治疗特定的复发/难治性滤泡性淋巴瘤患者以及特定的晚期上皮样肉瘤患者。和黄医药达成一项战略合作，负责在内地、香港、澳门和台湾进行他泽司他的研究、开发、生产以及商业化。沽空资料截至 2024-07-03 16:25。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00013":"和黄医药","BK4588":"碎股","HCM":"和黄医药","BK1587":"次新股","BK4007":"制药","BK1588":"回港中概股","BK4531":"中概回港概念","BK1191":"制药","BK4585":"ETF&股票定投概念"},"translate_title":"Chi-Med's (00013. HK) new drug marketing application for tazeistat has been accepted by the State Food and Drug Administration and has been given priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"和黄医药(00013.HK) 公布，他泽司他(tazemetostat)用于治疗复发或难治性滤泡性淋巴瘤成人患者的新药上市申请已获国家药监局受理并予以优先审评。他泽司他是由益普生(Ipsen)旗下公司Epizyme开发的全球同类首创的EZH2甲基转移酶抑制剂，已获美国食品药监局(FDA)加速批准用于治疗特定的复发/难治性滤泡性淋巴瘤患者以及特定的晚期上皮样肉瘤患者。日本厚生劳动省亦已批准其用于治疗特定的复发/难治性滤泡性淋巴瘤患者。和黄医药达成一项战略合作，负责在内地、香港、澳门和台湾进行他泽司他的研究、开发、生产以及商业化。(jl/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-03 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448457394"}